Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion · 2011
Overall survival of chronic myeloid leukemia patients treated with related donor hematopoietic stem cell transplant or imatinib.
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
López-Hernández Manuel Antonio, Alvarado-Ibarra Martha, González-Avante Crescencio Mauricio
Аннотация
OBJECTIVE: To determine the overall survival (OS) of Ph1 positive chronic myeloid leukemia (CML) patients treated with allogeneic hematopoietic stem cell transplant (AHSCT) vs. imatinib.
MATERIAL AND METHODS: We retrospectively included CML patients treated with related donor myeolablative and non-myeloablative AHSCT, between 1992 and 2009. Another group consisted of a patient cohort treated with imatinib between 2001 and 2009. The main variable was the persistence of hematologic remission.
RESULTS: The AHSCT/ imatinib groups included 36/46 patients, average age was 36/46, patients in chronic phase 34/44 and in blastic phase, 2/2. The number of myeloablative/non-myeloablative transplants was 28/8. Imatinib was administered at a dose of 400 to 800 mg/day (median 500 mg). The following events developed in both groups: death 14/3, hematological progression 4/5, 17/41 are alive and in hematological remission (p = 0.00009). The OS probability is 0.42 and 0.76 at 100 months (p = 0.0001). The decrease in absolute risk is 42%. The OS after 17 years remains unmodified in the AHSCT group after the first 6 years.
CONCLUSION: OS at 100 months is superior with imatinib than with AHSCT (p = 0.0001).
MATERIAL AND METHODS: We retrospectively included CML patients treated with related donor myeolablative and non-myeloablative AHSCT, between 1992 and 2009. Another group consisted of a patient cohort treated with imatinib between 2001 and 2009. The main variable was the persistence of hematologic remission.
RESULTS: The AHSCT/ imatinib groups included 36/46 patients, average age was 36/46, patients in chronic phase 34/44 and in blastic phase, 2/2. The number of myeloablative/non-myeloablative transplants was 28/8. Imatinib was administered at a dose of 400 to 800 mg/day (median 500 mg). The following events developed in both groups: death 14/3, hematological progression 4/5, 17/41 are alive and in hematological remission (p = 0.00009). The OS probability is 0.42 and 0.76 at 100 months (p = 0.0001). The decrease in absolute risk is 42%. The OS after 17 years remains unmodified in the AHSCT group after the first 6 years.
CONCLUSION: OS at 100 months is superior with imatinib than with AHSCT (p = 0.0001).
Предметные рубрики MeSH
AdolescentAdultAgedAntineoplastic AgentsBenzamidesChildChild, PreschoolFemaleHematopoietic Stem Cell TransplantationHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLiving DonorsLongitudinal StudiesMaleMiddle AgedPiperazinesPyrimidinesRetrospective StudiesSurvival RateYoung Adult